Instytut Zdrowia Dr Boczarska-Jedynak Sp. z o.o. S.K. — Clinical Trial Site

42 Registered trials

16 Currently recruiting

Organisation

Instytut Zdrowia Dr Boczarska-Jedynak Sp. z o.o. S.K.

Location

Oswiecim, Poland

Identifier

ORG-100042991

Address

Ul. Gen. Jaroslawa Dabrowskiego 4, 32-600, Poland

Departments

-
#40535: N/A
#616003 Neurologia
616008: neurology
616015: neurology
Chronic pain
Dermatology
Instytut Zdrowia Dr Boczarska- Jedynak Sp. z o.o. S.k.
Instytut Zdrowia Dr Boczarska-Jedynak Sp. z o.o., Sp. k.
KLINIKA NEUROLOGII I MEDYCYNY REGENERACYJNEJ
N/A
NA
Neurology
not applicable/nie dotyczy
Poradnia dermatologiczna i wenerologiczna, dział badań klinicznych
Poradnia Neurologiczna
unknown

Clinical trials at this site (42)

Search interface

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc… Ended

2023-506515-18-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-10-23
A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib… Halted

2024-516672-16-00 Multiple Sclerosis 5 2024-02-02
A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended

2023-508821-28-00 Migraine 4 2024-08-14
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy Ended

2022-502713-29-00 Dyskinesia due to cerebral palsy (DCP) 5 2024-03-01
Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended

2023-507358-34-00 For the treatment of patients with chronic non-specific 4 2024-02-13
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adult… Ended

2022-502552-31-00 Relapsing Forms of Multiple Sclerosis 4 2023-10-03
An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study) Ended

2022-501850-12-00 Psoriasis 4 2023-03-15
C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended

2024-513269-37-00 Migraine attacks with or without aura 6 2023-03-14
C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan… Ended

2024-513270-21-00 migraine headaches with or without aura 6 2023-03-14
An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis… Ended

2022-500424-30-00 Parkinson’s disease 4 2022-12-28
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended

2023-505645-12-00 Parkinson's Disease 4 2022-11-28
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the S… Ended

2024-511610-20-00 Alzheimer's Disease 4 2022-11-08
A multi site clinical trial to evaluate the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic pain Ended

2024-514934-19-00 Post-surgical neuropathic pain 5 2021-11-08
Eptinezumab as Preventive Treatment of Migraine in Adults with Migraine Ended

2023-510183-12-00 Chronic migraine 5 2021-07-05
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended

2023-506918-45-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended

2023-506919-18-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's … Ended

2023-504990-19-00 Agitation in Patients With Dementia of the Alzheimer's 5 2021-04-06
A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of iN1011-N17-02 in Patients with Post herpetic Neur… Ended

2024-518747-38-00 Post herpetic Neuralgia 4